ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 042,95
-0,63%
Dow Jones
41 985,35
0,08%
DAX
22 891,68
-0,53%
Brent Oil
71,775
0,00%
Bitcoin
84 206,51
0,19%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Context Therapeutics Inc (CNTX)

  7. Context Therapeutics Inc (CNTX) Actualités

CNTX

Context Therapeutics (CNTX)

Context Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CNTX
DateHeureSourceTitreSymboleSociété
20/03/202521h44Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CNTXContext Therapeutics Inc
20/03/202521h22GlobeNewswire Inc.Context Therapeutics Reports Full Year 2024 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
20/03/202521h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CNTXContext Therapeutics Inc
28/02/202522h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
24/02/202523h05GlobeNewswire Inc.Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CNTXContext Therapeutics Inc
19/02/202513h30GlobeNewswire Inc.Context Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
14/02/202523h09Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CNTXContext Therapeutics Inc
14/02/202522h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTXContext Therapeutics Inc
14/01/202522h58GlobeNewswire Inc.Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76NASDAQ:CNTXContext Therapeutics Inc
13/01/202513h30GlobeNewswire Inc.Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of DirectorsNASDAQ:CNTXContext Therapeutics Inc
02/12/202422h20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CNTXContext Therapeutics Inc
15/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CNTXContext Therapeutics Inc
14/11/202423h05Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CNTXContext Therapeutics Inc
06/11/202422h42Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CNTXContext Therapeutics Inc
06/11/202422h06GlobeNewswire Inc.Context Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
06/11/202422h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
23/10/202413h30GlobeNewswire Inc.Context Therapeutics to Participate in Upcoming Investor Conferences in NovemberNASDAQ:CNTXContext Therapeutics Inc
16/10/202413h30GlobeNewswire Inc.Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:CNTXContext Therapeutics Inc
04/09/202413h30GlobeNewswire Inc.Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of DirectorsNASDAQ:CNTXContext Therapeutics Inc
07/08/202422h17GlobeNewswire Inc.Context Therapeutics Reports Second Quarter 2024 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
01/08/202423h15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CNTXContext Therapeutics Inc
01/08/202413h30GlobeNewswire Inc.Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical OperationsNASDAQ:CNTXContext Therapeutics Inc
24/07/202423h07Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CNTXContext Therapeutics Inc
24/07/202422h55Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNTXContext Therapeutics Inc
12/07/202422h04Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CNTXContext Therapeutics Inc
10/07/202413h30GlobeNewswire Inc.Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95NASDAQ:CNTXContext Therapeutics Inc
31/05/202422h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CNTXContext Therapeutics Inc
24/05/202422h15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CNTXContext Therapeutics Inc
16/05/202422h01Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CNTXContext Therapeutics Inc
08/05/202422h06GlobeNewswire Inc.Context Therapeutics Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CNTX

Dernières Valeurs Consultées

EU
ACA
Credit Agricole
EU
MC
Lvmh Moet Hennessy Louis...
EU
SGO
Cie de SaintGobain
EU
CS
Axa
NYSE
MCD
McDonalds
EU
RI
Pernod Ricard
EU
AI
Air Liquide
EU
GLE
Societe Generale
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
EU
DG
Vinci
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo
France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces